Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients.

× No keyword cloud information.

9 in total

1. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.

Authors: Reuben Ramphal
Journal: Clin Infect Dis Date: 2004-07-15 Impact factor: 9.079

2. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors: A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal: Antimicrob Agents Chemother Date: 1996-05 Impact factor: 5.191

3. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

Authors: A Cometta; T Calandra; J Bille; M P Glauser
Journal: N Engl J Med Date: 1994-04-28 Impact factor: 91.245

4. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors: W V Kern; A Cometta; R De Bock; J Langenaeken; M Paesmans; H Gaya
Journal: N Engl J Med Date: 1999-07-29 Impact factor: 91.245

5. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.

Authors: A Freifeld; D Marchigiani; T Walsh; S Chanock; L Lewis; J Hiemenz; S Hiemenz; J E Hicks; V Gill; S M Steinberg; P A Pizzo
Journal: N Engl J Med Date: 1999-07-29 Impact factor: 91.245

Review 6. Moxifloxacin: a review of its use in the management of bacterial infections.

Authors: Gillian M Keating; Lesley J Scott
Journal: Drugs Date: 2004 Impact factor: 9.546

7. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

Authors: A Cometta; W V Kern; R De Bock; M Paesmans; M Vandenbergh; F Crokaert; D Engelhard; O Marchetti; H Akan; A Skoutelis; V Korten; M Vandercam; H Gaya; A Padmos; J Klastersky; S Zinner; M P Glauser; T Calandra; C Viscoli
Journal: Clin Infect Dis Date: 2003-07-22 Impact factor: 9.079

8. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.

Authors: C-J Soussy; J Nguyen; F Goldstein; H Dabernat; A Andremont; R Leclercq; H Drugeon; P Cavallo; H Chardon; J Etienne; Y Rio; P Courvalin
Journal: Clin Microbiol Infect Date: 2003-10 Impact factor: 8.067

9. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.

Authors: Kenneth V I Rolston; Susan Frisbee-Hume; Barbara LeBlanc; Harriet Streeter; Dah Hsi Ho
Journal: Diagn Microbiol Infect Dis Date: 2003-10 Impact factor: 2.803

9 in total

2 in total

1. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.

Authors: Kenneth V I Rolston; Susan E Frisbee-Hume; Shreyaskumar Patel; Ellen F Manzullo; Robert S Benjamin
Journal: Support Care Cancer Date: 2009-04-22 Impact factor: 3.603

2. Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer.

Authors: Sheng Zhang; Qing Wang; Yun Ling; Xichun Hu
Journal: BMC Cancer Date: 2015-02-06 Impact factor: 4.430

2 in total